Stevanato Group (STVN) Stock Price, News & Analysis

Company Overview

Stevanato Group S.p.A. is an Italy-based provider of drug-containment, drug-delivery and diagnostic solutions for the pharmaceutical, biotechnology and healthcare industries. The company serves customers across the development, production and administration of injectable medicines, with activities spanning pharmaceutical glass packaging, medical devices and manufacturing technologies.

Its product portfolio includes glass vials, cartridges, syringes and other primary containers, as well as ready-to-use packaging solutions such as EZ-fill. Stevanato Group also supplies drug-delivery systems, including components and devices for injectable therapies, along with inspection machines, assembly and packaging equipment, and related engineering and analytical services.

Founded in 1949 by Giovanni Stevanato, the company has expanded from its Italian origins into an international organization serving pharmaceutical and biotechnology customers in Europe, North America, Asia and other global markets. Stevanato Group is headquartered in Piombino Dese, Italy, and has been led by Executive Chairman Franco Stevanato, a member of the founding family.

Key Stats

• Today's Range: €19.22 to €19.82
• 50-Day Range: €19.30 to €22.70
• 52-Week Range: €12.89 to €27.99
• Volume: 267,000 shs
• Average Volume: 502,975 shs
• Market Capitalization: €5.88 billion
• P/E Ratio: 34.68
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

Stevanato Group Stock Analysis - MarketRank™

Stevanato Group scored higher than 68% of companies evaluated by MarketBeat, and ranked 387th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Stevanato Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 2 strong buy ratings, 2 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Stevanato Group has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 17.39%

Earnings Growth

Earnings for Stevanato Group are expected to grow by 17.39% in the coming year, from €0.69 to €0.81 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Stevanato Group is 34.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 41.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Stevanato Group is 34.68, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 202.00.

Price to Earnings Growth Ratio

Stevanato Group has a PEG Ratio of 1.57. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Stevanato Group has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.36% of the float of Stevanato Group has been sold short.

Short Interest Ratio / Days to Cover

Stevanato Group has a short interest ratio ("days to cover") of 3.47, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Stevanato Group has recently decreased by 8.01%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: N/A

Dividend Yield

Stevanato Group does not currently pay a dividend.

Dividend Growth

Stevanato Group has only been increasing its dividend for 1 years.

Dividend Sustainability

Based on earnings estimates, Stevanato Group will have a dividend payout ratio of 7.41% next year. This indicates that Stevanato Group will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.42

News Sentiment

Stevanato Group has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Stevanato Group this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Stevanato Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought €0.00 in company stock and sold €459,738.00 in company stock.

Percentage Held by Insiders

0.70% of the stock of Stevanato Group is held by insiders.

Percentage Held by Institutions

Stevanato Group has minimal institutional ownership at this time.

Company Calendar

• Record date for 7/29 Dividend: 6/11/2026
• Ex-Dividend for 7/29 Dividend: 6/11/2026
• Dividend Payable: 7/29/2026
• Last Earnings: 8/05/2026
• Today: 10/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:STVN
• CIK: 1849853
• Web: www.stevanatogroup.com
• Phone: 39049931811
• Fax: N/A
• Employees: 6,010
• Year Founded: 1949

Profitability

• EPS (Trailing Twelve Months): €0.56
• Trailing P/E Ratio: 34.68
• Forward P/E Ratio: 28.15
• P/E Growth: 1.57
• Net Income: €158.21 million
• Net Margins: 10.99%
• Pretax Margin: 15.59%
• Return on Equity: 10.43%
• Return on Assets: 6.16%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 1.61
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: €1.34 billion
• Price / Sales: 4.38
• Cash Flow: €0.89 per share
• Price / Cash Flow: 21.78
• Book Value: €5.55 per share
• Price / Book: 3.50

Miscellaneous

• Outstanding Shares: 302,840,000
• Free Float: 300,723,000
• Market Cap: €5.88 billion
• Optionable: Optionable
• Beta: 0.78